Sitagliptin for Acute Graft-Versus-Host Disease Prevention in Alternative Donor Transplantation: A Randomized Phase III Trial
Source: View publication →
The addition of sitagliptin to standard ATG-based prophylaxis in patients undergoing alternative donor hematopoietic stem-cell transplantation significantly reduced the incidence of grade II-IV acute graft-versus-host disease by day +100 without compromising engraftment or increasing relapse risk.
Key Findings
Study Design
Study Limitations
Clinical Significance
This study demonstrates that repurposing sitagliptin, an oral DPP-4 inhibitor typically used for type 2 diabetes, offers an effective strategy to mitigate early acute GVHD—particularly severe and intestinal forms—in high-risk alternative donor (haploidentical or matched unrelated) stem cell transplants. Because acute GVHD remains a leading cause of early post-transplant morbidity and mortality, adding a well-tolerated, short-course oral agent to standard ATG-based regimens represents a promising, accessible strategy to improve early GVHD-free, relapse-free survival without compromising the graft-versus-leukemia effect or increasing infection rates.
Historical Context
Graft-versus-host disease (GVHD) has historically been one of the major barriers to successful allogeneic hematopoietic stem-cell transplantation (HSCT), particularly in haploidentical and unrelated donor transplants. Standard prophylaxis often involves multi-agent immunosuppression, such as post-transplant cyclophosphamide or antithymocyte globulin (ATG) combined with calcineurin inhibitors and methotrexate. Even with these modern regimens, rates of acute GVHD, particularly lower gastrointestinal tract involvement, remain substantial. Dipeptidyl peptidase-4 (DPP-4), also known as CD26, is highly expressed on T-cells and is involved in T-cell activation and trafficking. Early phase and preclinical studies previously suggested that DPP-4 inhibition with sitagliptin could impair T-cell alloreactivity and reduce GVHD while preserving regulatory T-cells. This 2026 phase III trial builds on those mechanistic insights, providing definitive randomized evidence that DPP-4 inhibition safely and effectively reduces early severe acute GVHD when added to a contemporary ATG-based prophylactic backbone.
Guided Discussion
High-yield insights from every perspective
What is the mechanistic rationale for using sitagliptin, a drug classically prescribed for type 2 diabetes, to prevent acute graft-versus-host disease (aGVHD) in hematopoietic stem cell transplant recipients?
Key Response
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. In immunology, DPP-4 is also known as CD26, a cell-surface glycoprotein that is highly expressed on T cells. Blocking CD26 with sitagliptin impairs T-cell costimulation, activation, and migration. This dampens the alloreactive T-cell response responsible for aGVHD without fully ablating the graft-versus-leukemia (GVL) effect, demonstrating a fascinating cross-disciplinary application of a metabolic drug.
In the management of patients receiving alternative donor transplants, how does the addition of sitagliptin to standard ATG-based prophylaxis alter the traditional balance of transplant complications (GVHD, engraftment, and relapse)?
Key Response
Historically, intensifying immunosuppression to prevent GVHD trades off by increasing the risks of delayed engraftment, opportunistic infections, and disease relapse (due to loss of the GVL effect). The study highlights that sitagliptin reduces grade II-IV aGVHD by day +100 without compromising engraftment or increasing relapse risk, offering a unique clinical advantage in post-transplant management by uncoupling GVHD prevention from generalized immune suppression.
Considering the rapid adoption and high efficacy of post-transplant cyclophosphamide (PTCy) in alternative donor and haploidentical transplants, how might sitagliptin plus ATG compare to or integrate into the evolving landscape of PTCy-based GVHD prophylaxis?
Key Response
PTCy has revolutionized alternative donor transplants by robustly depleting alloreactive T-cells, but it can be associated with delayed immune reconstitution and cardiac toxicity. Fellows must critically evaluate whether sitagliptin+ATG can compete with PTCy as a standard backbone, or if sitagliptin might eventually be combined with PTCy to further optimize GVHD prevention while minimizing overlapping toxicities.
Given the favorable safety and efficacy profile of repurposing sitagliptin for aGVHD prophylaxis, what specific patient comorbidities or institutional factors would prompt you to adopt this regimen over conventional calcineurin inhibitor-based backbones in your practice?
Key Response
Attendings must weigh practical toxicity profiles. Standard regimens rely heavily on calcineurin inhibitors (like tacrolimus), which carry significant nephrotoxic, neurotoxic, and hypertensive risks. Sitagliptin's lack of nephrotoxicity makes it highly attractive for older patients or those with baseline renal impairment, providing a compelling, organ-sparing alternative for GVHD prophylaxis without sacrificing the GVL effect.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
From a translational immunology perspective, what correlative biomarker studies should be designed alongside this Phase III trial to elucidate the precise immunomodulatory effects of systemic CD26 inhibition on regulatory T cells (Tregs) versus alloreactive effector T cells?
Key Response
While the clinical outcomes are positive, the exact mechanistic uncoupling of GVHD from GVL via CD26 inhibition requires deep immunophenotyping. A rigorous researcher would design flow cytometry and transcriptomic studies to investigate how sitagliptin affects Treg preservation, chemokine cleavage (e.g., CXCL10), and T-cell receptor repertoire diversity to fully map the differential impact on alloreactivity versus leukemia-specific immunity.
In evaluating this Phase III trial for publication, what competing risks must be rigorously accounted for in the statistical analysis to validate the day +100 grade II-IV aGVHD endpoint, and how might improper handling of these risks skew the results?
Key Response
A seasoned editor would heavily scrutinize the statistical methodology, ensuring that competing risk models (e.g., the Fine-Gray method) were appropriately used. If patients die early from infection, toxicity, or relapse before day 100, they cannot develop aGVHD. Failure to statistically account for early non-relapse mortality as a competing risk could falsely lower the perceived aGVHD incidence, artificially inflating the apparent efficacy of sitagliptin.
Based on this Phase III data, should the ASTCT/ASBMT guidelines be updated to incorporate sitagliptin + ATG as a preferred Category 1 recommendation for GVHD prophylaxis in alternative donor HSCT, and how does this impact current recommendations favoring PTCy?
Key Response
Guideline committees must evaluate the strength of this Phase III evidence (Level 1) against existing standards. Current guidelines heavily feature PTCy or calcineurin-inhibitor based regimens for alternative donor transplants. If the reduction in aGVHD is substantial without survival or relapse detriments, the committee must determine if sitagliptin warrants a new, strong recommendation, perhaps as a preferred option for calcineurin-intolerant patients, and clearly define its hierarchy relative to PTCy.
Clinical Landscape
Noteworthy Related Trials
BMT CTN 1203 / PROGRESS I Trial
Tested
Three novel regimens tested: PTCy, Bortezomib, or Maraviroc based
Population
Patients undergoing reduced-intensity conditioning allogeneic HSCT
Comparator
Contemporary standard of care (Tacrolimus + Methotrexate)
Endpoint
GVHD-free, relapse-free survival (GRFS) at 1 year
ABA2 Trial
Tested
Abatacept + standard calcineurin inhibitor and methotrexate
Population
Patients undergoing unrelated donor allogeneic HSCT
Comparator
Standard calcineurin inhibitor and methotrexate alone
Endpoint
Grade III-IV acute GVHD-free survival at day 100
BMT CTN 1703 Trial
Tested
Post-transplant cyclophosphamide + Tacrolimus + Mycophenolate mofetil
Population
Adults undergoing reduced-intensity allogeneic HSCT
Comparator
Tacrolimus + Methotrexate
Endpoint
GVHD-free, relapse-free survival (GRFS) at 1 year
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis